Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European shares seen lower

Tue, 31st Jan 2023 07:36

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

EUROPEAN SHARES SEEN LOWER (0730 GMT)

European shares were set to open lower on Tuesday ahead of preliminary GDP readings, which investors will be watching closely to assess how the region's economy is going just as the European Central Bank prepares to raise rates again this week.

EuroSTOXX50 futures fell 0.3% following losses in Asia, where angst over upcoming central bank decisions, including also from the Federal Reserve, weighed after a strong start of the year. U.S. futures were broadly unchanged.

It's also a big week for earnings. Swiss bank UBS beat estimates in its latest quarter, but predicted an "uncertain" year ahead, plagued by accelerating inflation and higher rates. Its shares were seen rising slightly.

In Asia, Samsung Electronics indicated it did not plan to cut investment in chips, even after the South Korean group posted its smallest quarterly profit in eight years.

Later on in the U.S., Exxon Mobil is the first of the oil majors to report, while drugmaker Pfizer and automotive group GM also release quarterly numbers.

MIND THE GAP (0656 GMT)

An impressive 6% rally in global stocks this month, the first gain in January after three years, has got investors all excited after a dismal 2022.

Fundamentally, prospects for the world economy are not as bad as feared just a few months ago, prompting the International Monetary Fund to raise its 2023 global growth outlook slightly.

The IMF cited "surprisingly resilient" demand in the United States and Europe, easing of energy costs and the reopening of China's economy.

Still, it would be wise for investors to be mindful of a gap between expectations and reality.

On Monday, hotter-than-expected inflation data from Spain and an unexpected decline in the German economy in the fourth quarter created uneasiness for stock bulls, dragging down European shares.

Asian equities fell 1% on Tuesday and the dollar was eyeing a fourth monthly loss as investors reckon a peak in U.S. interest rates could swing into view as soon as this week's Federal Reserve meeting.

Flash GDP numbers are due from the euro zone, along with growth data for France and Italy. The numbers are likely to be keenly watched for signs on how weary economies are faring.

The ECB is all but certain to raise rates by half a percentage point on Thursday but fresh inflation data is still crucial for the central bank's policy guidance for subsequent meetings.

The Bank of England is set to raise rates by 50 bps to 4.0%, respectively. Headline inflation moderated in December to 10.5%, but it's still over five times its official target.

Money market bets show that the U.S. Federal Reserve is set to raise its policy rate by 25 basis points to 4.50%-4.75% on Wednesday.

Adding to pressure on British finance minister Jeremy Hunt to come up with a growth plan, the country became the only Group of Seven nation to suffer a cut to its 2023 economic growth outlook in IMF forecasts published on Tuesday.

Britain's flagging economy now appears set to shrink by 0.6% this year, a sharp downgrade from previously expected growth of 0.3% in the IMF's last forecast in October.

Meanwhile, a U.S. federal appeals court ruled on Monday that drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount programme, marking a victory for Sanofi, Novo Nordisk and AstraZeneca.

Finally, there's good news for tech staff. With thousands of layoffs taking place in Silicon Valley, some German companies, faced with a tight labour market and a shortage of workers with key software engineering skills, are seizing on the West Coast's woes as an opportunity to recruit top talent.

Key developments that could influence markets on Tuesday:

Economic data: Euro zone Q4 flash GDP; France Q4 GDP, Jan CPI flash; Germany Dec import prices, retail sales, flash CPI; Italy preliminary Q4 GDP

Speakers: Swedish central bank governor Erik Thedeen participates in an open hearing on financial stability in the Swedish economy in Stockholm

European results: UBS, Swedbank

U.S. economic data: Q4 employment wages, Q4 Nov house prices

U.S. Federal Reserve begins two-day meeting

U.S. results: Exxon Mobil, Caterpillar, General Motors, Pfizer, McDonald's, UPS

More News
10 Nov 2022 16:34

Sanofi, GSK score late win with EU COVID booster approval

Nov 10 (Reuters) - Sanofi said on Thursday it won European Union approval for its COVID-19 vaccine booster, jointly made with British partner GSK, after a drawn-out development effort that saw the pair fall behind now-dominant vaccine suppliers.

Read more
4 Nov 2022 07:00

Sanofi, Astra win EU approval for prevention of infant RSV

Nov 4 (Reuters) - The European Commission on Friday approved Sanofi and AstraZeneca's Beyfortus for the prevention of a common and highly contagious type of respiratory infections in infants.

Read more
2 Nov 2022 15:47

New GSK maintains strong start, but Zantac litigation looms large

Q3 profit, sales beat expectations

*

Read more
29 Sep 2022 11:44

Oddo BHF flags European pharma's attractive growth profile, prefers Novo Nordisk, AstraZeneca

Read more
26 Sep 2022 15:22

GSK selects Burberry's Brown as its first female CFO

Brown to join GSK in April

*

Read more
20 Sep 2022 08:58

Haleon believes it is not liable for any potential Zantac liabilities

LONDON, Sept 20 (Reuters) - Haleon believes it is not liable for any claims that may arise from U.S. litigation over the heartburn drug Zantac, the London-listed company's CEO Brian McNamara told Reuters on Tuesday.

Read more
20 Sep 2022 07:14

Haleon rejects Zantac indemnification requests from GSK, Pfizer

LONDON, Sept 20 (Reuters) - Haleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.

Read more
5 Sep 2022 15:24

Sanofi sees EU regulatory decision on its COVID booster in weeks

BRUSSELS, Sept 5 (Reuters) - The European Union's drugs regulator may be a few weeks from deciding whether to approve the experimental COVID-19 vaccine developed by French drugmaker Sanofi and its British partner GSK, a Sanofi executive said on Monday.

Read more
30 Aug 2022 17:14

European stocks fall for third day as rate hike, recession fears grow

Aug 30 (Reuters) - European shares ended lower on Tuesday, failing to shrug off fears of higher interest rates amid a burgeoning energy crisis and looming recession.

Read more
17 Aug 2022 18:10

Sanofi trial failure halts work on breast cancer treatment amcenestrant

Aug 17 (Reuters) - Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.

Read more
17 Aug 2022 17:22

European shares slip on inflation worries, Germany leads fall

Aug 17 (Reuters) - European shares slid on Wednesday and bond yields rallied after a sharp rise in UK inflation brought the spotlight back to more monetary tightening amid data which showed euro zone economic growth was slightly less robust in the second quarter.

Read more
17 Aug 2022 15:15

Plaintiff in first Zantac lawsuit set for trial drops case

Aug 17 (Reuters) - The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.

Read more
17 Aug 2022 08:21

GSK shares ease after plaintiff in first Zantac lawsuit drops case

LONDON, Aug 17 (Reuters) - Shares in GlaxoSmithKline fell slightly in early trading on Wednesday but stayed above recent lows after the plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial agreed to drop his case.

Read more
15 Aug 2022 22:17

UK first to approve Omicron COVID shot with Moderna nod

LONDON, Aug 15 (Reuters) - Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus.

Read more
12 Aug 2022 17:17

European shares rise as healthcare, leisure stocks gain

Aug 12 (Reuters) - European shares rose on Friday after drugmakers rebounded following a slump in the previous session, and Flutter fanned a rally in the travel and leisure sector after an upbeat earnings forecast.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.